Children and Adolescents with Early Treated Phenylketonuria: Cognitive Development and Fluctuations of Blood Phenylalanine Levels

Int J Environ Res Public Health. 2024 Apr 2;21(4):431. doi: 10.3390/ijerph21040431.

Abstract

Background: We assessed the relationship between the cognitive development of children and adolescents with phenylketonuria (PKU) and fluctuations in peripheral phenylalanine (Phe) levels.

Methods: We examined the neurocognitive performance of 33 children and adolescents with early treated PKU, of whom 18 were treated with sapropterin dihydrochloride, and 15 were on a classic diet. For 26 weeks, patients were assessed weekly for their blood phenylalanine (Phe) levels. Phe levels were analyzed for fluctuations indicated by the individual standard deviation. Fluctuations were compared to the standard deviation of 26 Phe level measurements before the study interval. We also assessed the concurrent IQ of the patients. This was repeated at one-, two-, and seven-year intervals.

Results: Full-scale IQ in patients treated with a classic diet did not change within the follow-up. In patients treated with Sapropterin dihydrochloride, however, there was a considerable gain in full-scale IQ. This was particularly true if blood Phe fluctuations increased in patients of this treatment group.

Conclusions: Sapropterin dihydrochloride enhances Phe tolerance in patients with PKU. Increasing blood Phe fluctuations following enhanced Phe tolerance may indicate that the treatment not only allows patients to relax their Phe-restricted diet but also may support cognitive development in patients.

Keywords: FSIQ; PKU; blood Phe variations; gain in function; phenylalanine.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Biopterins* / analogs & derivatives*
  • Biopterins* / blood
  • Child
  • Child Development / drug effects
  • Child, Preschool
  • Cognition* / drug effects
  • Female
  • Humans
  • Male
  • Phenylalanine* / blood
  • Phenylketonurias* / blood
  • Phenylketonurias* / drug therapy

Substances

  • Phenylalanine
  • Biopterins
  • sapropterin

Grants and funding

This research received funding from BioMarin Pharmaceutical Inc.